Committed to Finding New Treatments for Glioblastoma

Our team of internationally acclaimed neurologists and patented technologies offer a promising combination.

If you’re one of the 10,000 people in the USA diagnosed or a family member of one of the 17,000 patients that die each year from this horrific and incurable brain cancer, there is no cause with greater urgency. Nearly all patients diagnosed die within 12-18 months.

Some cancers, including brain cancer, have been historically underfunded despite the grim prognosis for those patients diagnosed. No doubt this is a direct corollary to why some cancers, like glioblastoma, have relatively few to no treatment options.

Research shows that 80% of the instances of recurrence, which are inevitable, appear in the tissue surrounding the resection cavity. The blood-brain barrier imposes biological limitations that make it easier for cancerous cells to invade the brain than it is for them to exit the brain and metastasize elsewhere. That sounds almost encouraging until you begin to discuss drug delivery: most therapeutics have high molecular weights beyond the range suitable for drug transport. Check point inhibitors which modulate biological pathways are generally effective in the treatment of most diseases: not so for glioblastoma.

Targeted delivery to transport highly selective inhibitors across the blood-brain barrier remains the next frontier for treatment. “Glioblastoma requires an arsenal to combat,” said Dr. TBD, “we view the combination of improved targeting with localized delivery of specific inhibitors designed to penetrate the blood-brain barrier, as a novel modality worthy of further exploration.” GCT has recently acquired two patents for medicinal compounds that are known to cross the blood-brain barrier: PI3K and Vps34 act in mechanistically distinct manners as potent inhibitors of pathways commonly associated with cancers.

“Global Cancer Technology is combining technologies in innovative ways to fight deadly diseases."

- Dr. Santosh Kesari
World-renowned Neuro-Oncologist-John Wayne Cancer Insitute

The future of treatment

“Indeed, transport across the blood-brain barrier has been a fantasy of neurologists for some time. Delivering inhibitors like PI3K and Vps34 directly to the brain tumor is an incredibly exciting approach, one that I’m personally honored to be involved in exploring.”
- Dr. Santosh Kesari
World-renowned Neuro-Oncologist-John Wayne Cancer Insitute

Here's your opportunity to own shares in GCT. For as little as $2 per share, you can invest in the future of cancer treatment.

The other inhibitor acquired by GCT targets Vps34, a PI3K isoform known to affect cellular mobility and autophagy. Inhibitors of Vps34 have been shown to impede the movement of cancerous cells and their ability to induce the “suicide” of surrounding healthy cells.

​Deducing how these inhibitors behave in glioblastoma patients requires further research. The ability to penetrate the blood-brain barrier is, in of itself, a tremendous advantage.

To sum up – there is an urgent need for novel treatments of glioblastoma. And several are in development.

“When successfully commercialized, the company will significantly impact cancer treatment outcomes and establish itself as a leader in this cancer treatment delivery market,” stated Dr. Santosh Kesari, world-renowned Neuro-Oncologist at John Wayne Cancer Institute.

Cancer Treatment

Global Cancer Technology has numerous patents and other IP that might lead to breakthroughs in cancer therapy. The company is partnering with highly acclaimed academic institutions such as Barrow Neurological Institute, UCSD, along with industry leaders, to make these therapies available to patients as quickly as possible.

Learn more about remote-controlled cancer drug delivery by clicking here.

Blocking cancer in its tracks

“Phosphatidylinositol 3-kinase (PI3K) is associated with cellular processes including cell death, protein synthesis and metabolism. PI3K has been shown to block this aberrant activity. Given the number of multimodal imaging methods that we are currently deploying to improve disease characterization and detection, particularly for brain cancers, we are eager to study how this inhibitor affects the progression of brain cancer.”

- Dr. Chad Quarles
Professor, Barrow Neurological Institute

SOURCES

  • People and Instances of Occurrence LINK and LINK

  • Patents (below)

The parent company & its subsidiaries have the following licenses:

  • License for US patent numbers 5,528,653, 5,757,866 and 6,512,813B1

  • License for International Application Number: PCT/US2014/053487

  • License for Patent Number US 9,019,078,B2

  • Source Registry CA 1050S102S

  • Device Registry CA 1050D101S

  • RGS Vertex360™ 510 K FDA # 060314

  • Explorer 3D™ 510k FDA # 991815

  • Explorer 4D™ 510k FDA # 093588 (CT)

  • Explorer 4D™ 510k FDA # 101220 (MRI)

  • ACCUSOURCE ™ 510K FDA # K051753

  • CE Mark and ISO certification: CE 0434, QA 2006-OSL-AQ-0661, QA 2007-OSL- MDD-0009

Here's your opportunity to own shares in GCT. For as little as $2 per share, you can invest in the future of cancer treatment.